A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Liang Zhuang, professor
- Phone Number: +8613006325115
- Email: mrzhuangliang@126.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Liang Zhuang, professor
- Phone Number: +8613006325115
- Email: mrzhuangliang@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 to 70 years;
- Diagnosis of unresectable or recurrent or metastatic biliary tract cancer (Ampulla of Vater, gallbladder, intra or extra-hepatic biliary ducts);
- Adequate bone marrow, liver and kidney function: absdute neutrophil count (ANC) ≥ 1.5 x 10^9/L, platelet count (PLT) ≥75 x 10^9/L, hemoglobin (HB) ≥ 75 g/L, White blood cell(WBC) ≥ 3.0 x 10^9/L, no bleeding symptoms or bleeding tendency; Total bilirubin (TBIL) ≤ 3 x upper limit of normal range (ULN), alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤ 5 x upper limit of normal range (ULN); creatinine(Cr) ≤ 1.5 x upper limit of normal range(ULN) or creatinine clearance rate(CCR)≥ 45ml/min;
- At least one measurable lesion;
- Karnofsky Performance Status(KPS) ≥ 70;
- Estimated life expectancy of at least 3 months;
- Resolution of all acute clinical toxic effects of any prior treatment to grade ≤ 1, with the exception of alopecia;
- Be able to understand and willingness to sign IRB-approved informed consent; (If the patient cannot sign the informed consent due to consciousness disorder, upper limbs paralysis or inability to write, the legal representative shall sign the informed consent on behalf of the patient).
Exclusion Criteria:
- Ongoing uncontrolled infections, or have received systemic antibiotic therapy within 72 hours prior to registration;
- Myeloproliferative disorder or any other hematopoietic function disorder;
- Have an untreated second malignancy or brain metastasis;
- Allergic to the chemotherapy drugs of this protocol;
- Unable to cooperate due to neurologic diseases or psychiatric illness;
- Pregnant or lactating female patients; Women of child-bearing age who refuse to accept contraceptive measures;
- Have other significant medical illness, for example,active tuberculosis, active pneumonia, uncorrected electrolyte disturbance, uncontrolled tumor associated pain, uncontrolled hydrothorax or seroperitoneum and so on;
- Patients need to receive other antitumor therapy at the same time;
- Have received any other experimental treatment or participated in another interventional clinical trial within 30 days prior to registration;
- Any other situation that the researcher considered patients are unsuitable for the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nab-paclitaxel + Cisplatin
Patients in this arm receive chemotherapy with Nab-paclitaxel plus Cisplatin
|
Nab-paclitaxel 125mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
|
|
Active Comparator: Gemcitabine + Cisplatin
Patients in this arm receive chemotherapy with Gemcitabine plus Cisplatin
|
Gemcitabine1000mg/m2 IV on D1,8 plus Cisplatin 75mg/m2 IV on D1 , every 21 days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PFS
Time Frame: up to 3 years
|
PFS is defined as time from the start of treatment to progression of disease or death.
|
up to 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ORR
Time Frame: up to 3 years
|
The rate of participants that achieve either a complete response (CR) or a partial response (PR).
|
up to 3 years
|
|
OS
Time Frame: up to 3 years
|
Overall survival is defined as time from the start of treatment until death due to any reason.
|
up to 3 years
|
|
TTP
Time Frame: up to 3 years
|
Time to progress is defined as time from randomized grouping to objective progression of tumors.
|
up to 3 years
|
|
AEs
Time Frame: up to 3 years
|
Adverse reactions refer to the occurrence and development of diseases in the process of using drugs according to normal usage and dosage to prevent, diagnose or treat diseases.Adverse reactions unrelated to the purpose of treatment.
|
up to 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Biliary Tract Diseases
- Biliary Tract Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Gemcitabine
- Paclitaxel
- Cisplatin
Other Study ID Numbers
Other Study ID Numbers
- CSPC-KAL-BTC-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.